Xl-Protein GMBH

xl-protein develops and commercializes its proprietary pasylation® technology to extend the plasma half-life of biopharmaceuticals. the genetic fusion (or chemical conjugation) with conformationally disordered amino acid sequences composed of the three small residues pro, ala, and/or ser ('pasylation') provides a simple way to attach a solvated biopolymer with large hydrodynamic volume to a therapeutic protein or peptide. this polypeptide adopts a bulky random coil structure, which significantly increases the size of the biopharmaceutical. by this means the typically rapid clearance of the biologically active component via kidney filtration is retarded by 1-2 orders of magnitude, depending on the length of the pas tag. compared with other strategies to prolong the plasma half-life of biologics the pasylation technology provides numerous advantages.